CryoPort, Inc. (NASDAQ:CYRX) Receives Average Rating of “Moderate Buy” from Analysts

CryoPort, Inc. (NASDAQ:CYRX) has received a consensus rating of “Moderate Buy” from the eleven ratings firms that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating, one has issued a hold rating, eight have issued a buy rating and one has issued a strong buy rating on the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $12.8333.

Several equities research analysts have recently issued reports on CYRX shares. KeyCorp raised shares of CryoPort from a “sector weight” rating to an “overweight” rating and set a $15.00 price objective for the company in a research report on Wednesday, August 6th. Stephens assumed coverage on CryoPort in a research note on Tuesday, July 22nd. They issued an “overweight” rating and a $13.00 price target on the stock. Leerink Partners raised CryoPort from a “market perform” rating to an “outperform” rating and set a $16.00 price objective for the company in a research report on Wednesday, August 6th. Weiss Ratings reissued a “sell (d+)” rating on shares of CryoPort in a research report on Wednesday, October 8th. Finally, UBS Group boosted their target price on CryoPort from $11.00 to $12.50 and gave the stock a “buy” rating in a research note on Wednesday, November 5th.

Insider Buying and Selling at CryoPort

In other news, Director Robert J. Hariri sold 25,000 shares of the company’s stock in a transaction on Thursday, September 11th. The shares were sold at an average price of $9.71, for a total value of $242,750.00. Following the completion of the transaction, the director owned 51,275 shares in the company, valued at approximately $497,880.25. This represents a 32.78% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 10.00% of the company’s stock.

Institutional Investors Weigh In On CryoPort

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Nisa Investment Advisors LLC grew its holdings in shares of CryoPort by 299.9% during the second quarter. Nisa Investment Advisors LLC now owns 3,639 shares of the company’s stock worth $27,000 after purchasing an additional 2,729 shares during the last quarter. Tower Research Capital LLC TRC lifted its holdings in shares of CryoPort by 300.1% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,833 shares of the company’s stock valued at $44,000 after purchasing an additional 4,375 shares during the last quarter. Whittier Trust Co. of Nevada Inc. acquired a new stake in shares of CryoPort in the 3rd quarter valued at about $53,000. CWM LLC grew its stake in CryoPort by 1,437.0% during the 1st quarter. CWM LLC now owns 11,328 shares of the company’s stock worth $69,000 after buying an additional 10,591 shares during the last quarter. Finally, ProShare Advisors LLC acquired a new position in CryoPort during the second quarter worth approximately $75,000. 92.90% of the stock is owned by hedge funds and other institutional investors.

CryoPort Stock Performance

Shares of CryoPort stock opened at $8.51 on Tuesday. The business has a 50-day simple moving average of $9.46 and a 200-day simple moving average of $8.11. The company has a debt-to-equity ratio of 0.39, a quick ratio of 15.47 and a current ratio of 16.24. CryoPort has a one year low of $4.58 and a one year high of $11.44. The company has a market cap of $426.09 million, a PE ratio of 6.40 and a beta of 1.58.

CryoPort (NASDAQ:CYRX) last issued its quarterly earnings results on Tuesday, November 4th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.05. CryoPort had a net margin of 37.21% and a negative return on equity of 9.79%. The company had revenue of $44.23 million during the quarter, compared to the consensus estimate of $41.22 million. CryoPort has set its FY 2025 guidance at EPS. On average, equities research analysts forecast that CryoPort will post -0.99 EPS for the current fiscal year.

CryoPort Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.